Response to eribulin in a patient with metastatic uterine leiomyosarcoma: a case report.

Abstract

We report the case of a 51 year-old patient affected by an advanced uterine leiomyosarcoma treated with eribulin as fourth-line therapy. The patient, with a previous history of leiomyomas of the myometrium, had undergone total hysterectomy for repeated metrorrhagias. After 7 years, metastases in the liver, bone and lung were documented. A fine needle liver biopsy demonstrated leiomyosarcoma metastasis. The patient was treated with first-line doxorubicin chemotherapy; after six cycles, disease progression was observed. A second-line trabectedin chemotherapy and a third-line gemcitabine chemotherapy were performed; no objective responses were seen after two cycles. The patient was then treated with eribulin on the basis of an EORTC Phase II trial showing preliminary activity in uterine leiomyosarcoma. After six cycles, CT scan showed partial remission of liver lesion. Disease progression was observed after nine cycles with eribulin, without severe side effects and preserving a good quality of life.

• Authors: Sandra Aliberti, Sara Miano, Francesco Tolomeo, Alessandra Merlini, Massimo Aglietta, Giovanni Grignani
• Journal: Future oncology (London, England) (Future Oncol) Vol. 16 Issue 1s Pg. 15-19 (Jan 2020) ISSN: 1744-8301 [Electronic] England
• PMID: 31916842 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Furans
• Ketones
• eribulin

Topics

• Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
• Biopsy
• Bone Marrow (pathology)
• Female
• Furans (administration & dosage, adverse effects, therapeutic use)
• Humans
• Ketones (administration & dosage, adverse effects, therapeutic use)
• Leiomyosarcoma (diagnosis, drug therapy)
• Magnetic Resonance Imaging
• Middle Aged
• Neoplasm Metastasis
• Neoplasm Staging
• Tomography, X-Ray Computed
• Treatment Outcome